Search

Your search keyword '"Koglin, Joerg"' showing total 182 results
Start Over Author "Koglin, Joerg"
182 results on '"Koglin, Joerg"'

1. Background Medical Therapy and Clinical Outcomes From the VICTORIA Trial

Author

Ezekowitz, Justin A., McMullan, Ciaran J., Westerhout, Cynthia M., Piña, Ileana L., Lopez-Sendon, Jose, Anstrom, Kevin J., Hernandez, Adrian F., Lam, Carolyn S.P., O’Connor, Christopher M., Pieske, Burkert, Ponikowski, Piotr, Roessig, Lothar, Voors, Adriaan A., Koglin, Joerg, Armstrong, Paul W., and Butler, Javed

Published
2023
Full Text
View/download PDF

3. Reassessing Phase II Heart Failure Clinical Trials

Author

Butler, Javed, Hamo, Carine E, Udelson, James E, O'Connor, Christopher, Sabbah, Hani N, Metra, Marco, Shah, Sanjiv J, Kitzman, Dalane W, Teerlink, John R, Bernstein, Harold S, Brooks, Gabriel, Depre, Christophe, DeSouza, Mary M, Dinh, Wilfried, Donovan, Mark, Frische-Danielson, Regina, Frost, Robert J, Garza, Dahlia, Gohring, Udo-Michael, Hellawell, Jennifer, Hsia, Judith, Ishihara, Shiro, Kay-Mugford, Patricia, Koglin, Joerg, Kozinn, Marc, Larson, Christopher J, Mayo, Martha, Gan, Li-Ming, Mugnier, Pierrre, Mushonga, Sekayi, Roessig, Lothar, Russo, Cesare, Salsali, Afshin, Satler, Carol, Shi, Victor, Ticho, Barry, van der Laan, Michael, Yancy, Clyde, Stockbridge, Norman, and Gheorghiade, Mihai

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Cardiovascular, Heart Disease, Clinical Trials and Supportive Activities, Cardiovascular Agents, Clinical Trials, Phase II as Topic, Consensus, Heart Failure, Humans, Research Design, Treatment Outcome, United States, United States Food and Drug Administration, clinical trial, heart failure, mortality, safety, Biochemistry and Cell Biology, Cardiorespiratory Medicine and Haematology, Medical Physiology, Cardiovascular System & Hematology, Cardiovascular medicine and haematology, Medical physiology
Abstract

The increasing burden and the continued suboptimal outcomes for patients with heart failure underlines the importance of continued research to develop novel therapeutics for this disorder. This can only be accomplished with successful translation of basic science discoveries into direct human application through effective clinical trial design and execution that results in a substantially improved clinical course and outcomes. In this respect, phase II clinical trials play a pivotal role in determining which of the multitude of potential basic science discoveries should move to the large and expansive registration trials in humans. A critical examination of the phase II trials in heart failure reveals multiple shortcomings in their concept, design, execution, and interpretation. To further a dialogue on the challenges and potential for improvement and the role of phase II trials in patients with heart failure, the Food and Drug Administration facilitated a meeting on October 17, 2016, represented by clinicians, researchers, industry members, and regulators. This document summarizes the discussion from this meeting and provides key recommendations for future directions.

Published
2017

5. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension

Author

Hoeper, Marius M., primary, Badesch, David B., additional, Ghofrani, H. Ardeschir, additional, Gibbs, J. Simon R., additional, Gomberg-Maitland, Mardi, additional, McLaughlin, Vallerie V., additional, Preston, Ioana R., additional, Souza, Rogerio, additional, Waxman, Aaron B., additional, Grünig, Ekkehard, additional, Kopeć, Grzegorz, additional, Meyer, Gisela, additional, Olsson, Karen M., additional, Rosenkranz, Stephan, additional, Xu, Yayun, additional, Miller, Barry, additional, Fowler, Marcie, additional, Butler, John, additional, Koglin, Joerg, additional, de Oliveira Pena, Janethe, additional, and Humbert, Marc, additional

Published
2023
Full Text
View/download PDF

7. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

Author

Green, Jennifer B., Bethel, Angelyn M., Armstrong, Paul W., Buse, John B., Engel, Samuel S., Garg, Jyotsna, Josse, Robert, Kaufman, Keith D., Koglin, Joerg, Korn, Scott, Lachin, John M., McGuire, Darren K., Pencina, Michael J., Standl, Eberhard, Stein, Peter P., Suryawanshi, Shailaja, Van de Werf, Frans, Peterson, Eric D., and Holman, Rury R.

Published
2015
Full Text
View/download PDF

9. CORONARY ARTERY DISEASE AND CARDIOVASCULAR OUTCOMES IN HEART FAILURE: INSIGHTS FROM THE VERICIGUAT GLOBAL STUDY IN SUBJECTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION (VICTORIA) TRIAL

Author

Armstrong, Paul Wayne, primary, Giraldo, Clara Ines Saldarriaga, additional, Atar, Dan, additional, Stebbins, Amanda, additional, Lewis, Basil, additional, Abidin, Imran, additional, Butler, Javed, additional, Ezekowitz, Justin, additional, Hernandez, Adrian, additional, Koglin, Joerg, additional, Lam, Carolyn, additional, O'Connor, Christopher, additional, Pieske, Burkert, additional, Ponikowski, Piotr, additional, Roessig, Lothar, additional, Voors, Adriaan, additional, and Anstrom, Kevin, additional

Published
2021
Full Text
View/download PDF

10. BASELINE CARDIAC TROPONIN T, CLINICAL OUTCOMES AND VERICIGUAT TREATMENT EFFECT IN HEART FAILURE WITH REDUCED EJECTION FRACTION STUDY: INSIGHTS FROM THE VICTORIA TRIAL

Author

DeFilippi, Christopher R., primary, Alemayehu, Wendimagegn, additional, Voors, Adriaan, additional, Kaye, David, additional, Anstrom, Kevin, additional, Butler, Javed, additional, Ezekowitz, Justin, additional, Hernandez, Adrian, additional, Koglin, Joerg, additional, Lam, Carolyn, additional, Pieske, Burkert, additional, Ponikowski, Piotr, additional, Roessig, Lothar, additional, Seliger, Stephen, additional, Westerhout, Cynthia, additional, Armstrong, Paul, additional, and O’Connor, Christopher, additional

Published
2021
Full Text
View/download PDF

11. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction

Author

Armstrong, Paul W, Pieske, Burkert, Anstrom, Kevin J, Ezekowitz, Justin, Hernandez, Adrian F, Butler, Javed, Lam, Carolyn S P, Ponikowski, Piotr, Voors, Adriaan A, Jia, Gang, McNulty, Steven E, Patel, Mahesh J, Roessig, Lothar, Koglin, Joerg, O'Connor, Christopher M, VICTORIA Study Group, University of Zurich, and Armstrong, Paul W

Subjects
610 Medicine & health, 2700 General Medicine, 11171 Cardiocentro Ticino
Published
2020
Full Text
View/download PDF

16. The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase

Author

Ong, Andrew T.L., Serruys, Patrick W., Mohr, Frederick W., Morice, Marie-Claude, Kappetein, A. Pieter, Holmes, David R., Jr., Mack, Michael J., van den Brand, Joerg, Morel, Marie-Angele, van Es, Gerrit-Anne, Kleijne, Jeroen, Koglin, Joerg, and Russell, Mary E.

Subjects
Coronary heart disease -- Care and treatment, Coronary artery bypass -- Patient outcomes, Coronary artery bypass -- Research, Transluminal angioplasty -- Patient outcomes, Transluminal angioplasty -- Research, Stent (Surgery) -- Research, Health
Published
2006

17. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: A randomized controlled trial

Author

Stone, Gregg, W., Cannon, Louis, O'Shaughnessy, Charles D., Hall, Patrick, Koglin, Joerg, Ellis, Stephen G., Mann, J. Tift, Greenberg, Joel D., Spriggs, Douglas, DeMaio, Samuel, Popma, Jeffrey J., and Russell, Mary E.

Subjects
Paclitaxel -- Dosage and administration, Stent (Surgery) -- Research, Coronary heart disease -- Care and treatment, Clinical trials
Abstract

A study investigated the safety and efficacy of the polymer-based, slow-release paclitaxel-eluting stent in a patient population with more complex lesions than previously studied. Results revealed that compared with a bare metal stent, implantation of the paclitaxel-eluting stent effectively reduces clinical and angiographic restenosis in patients with complex lesions.

Published
2005

18. Effect Of Vericiguat In Victoria According To Guideline-directed Medical Therapy

Author

Ezekowitz, Justin, primary, McMullan, Ciaran, additional, Westerhout, Cynthia, additional, Pina, Ileana L., additional, Lopez-Sendon, Jose, additional, Anstrom, Kevin J., additional, Hernandez, Adrian F., additional, Lam, Carolyn S.P., additional, O'Connor, Christopher M., additional, Pieske, Burkert, additional, Ponikowski, Piotr, additional, Roessig, Lothar, additional, Voors, Adriaan A., additional, Koglin, Joerg, additional, Armstrong, Paul W., additional, and Butler, Javed, additional

Published
2020
Full Text
View/download PDF

19. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document

Author

Zannad, Faiez, Garcia, Angeles Alonso, Anker, Stefan D., Armstrong, Paul W., Calvo, Gonzalo, Cleland, John G.F., Cohn, Jay N., Dickstein, Kenneth, Domanski, Michael J., Ekman, Inger, Filippatos, Gerasimos S., Gheorghiade, Mihai, Hernandez, Adrian F., Jaarsma, Tiny, Koglin, Joerg, Konstam, Marvin, Kupfer, Stuart, Maggioni, Aldo P., Mebazaa, Alexandre, Metra, Marco, Nowack, Christina, Pieske, Burkert, Piña, Ileana L., Pocock, Stuart J., Ponikowski, Piotr, Rosano, Giuseppe, Ruilope, Luis M., Ruschitzka, Frank, Severin, Thomas, Solomon, Scott, Stein, Kenneth, Stockbridge, Norman L., Stough, Wendy Gattis, Swedberg, Karl, Tavazzi, Luigi, Voors, Adriaan A., Wasserman, Scott M., Woehrle, Holger, Zalewski, Andrew, and McMurray, John J.V.

Published
2013
Full Text
View/download PDF

21. Non-participation in a Heart Failure Clinical Trial: Perspectives and Opportunities from the VICTORIA Trial and Simultaneous Registry

Author

Ezekowitz, Justin, primary, Mentz, Robert J., additional, Westerhout, Cynthia M., additional, Sweitzer, Nancy K., additional, Givertz, Michael M., additional, Piña, Ileana L., additional, O'Connor, Christopher M., additional, Greene, Stephen J., additional, Koglin, Joerg, additional, Roessig, Lothar, additional, Hernandez, Adrian F., additional, and Armstrong, Paul W., additional

Published
2020
Full Text
View/download PDF

22. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction

Author

Armstrong, Paul W., primary, Pieske, Burkert, additional, Anstrom, Kevin J., additional, Ezekowitz, Justin, additional, Hernandez, Adrian F., additional, Butler, Javed, additional, Lam, Carolyn S.P., additional, Ponikowski, Piotr, additional, Voors, Adriaan A., additional, Jia, Gang, additional, McNulty, Steven E., additional, Patel, Mahesh J., additional, Roessig, Lothar, additional, Koglin, Joerg, additional, and O’Connor, Christopher M., additional

Published
2020
Full Text
View/download PDF

27. Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial.

Author

Voors, Adriaan A., Mulder, Hillary, Reyes, Eugene, Cowie, Martin R., Lassus, Johan, Hernandez, Adrian F., Ezekowitz, Justin A., Butler, Javed, O'Connor, Christopher M., Koglin, Joerg, Lam, Carolyn S.P., Pieske, Burkert, Roessig, Lothar, Ponikowski, Piotr, Anstrom, Kevin J., and Armstrong, Paul W.

Subjects
KIDNEY physiology, HEART failure patients, HEART failure, EPIDERMAL growth factor receptors, GLOMERULAR filtration rate
Abstract

Aims: Vericiguat reduced the primary composite outcome of cardiovascular death or heart failure (HF) hospitalization in patients with worsening HF with reduced ejection fraction (HFrEF) and a lower limit of baseline estimated glomerular filtration rate (eGFR) of 15 mL/min/1.73 m2. We evaluated the relationship between the efficacy of vericiguat and baseline and subsequent changes in renal function. Methods and results: In VICTORIA, core laboratory serum creatinine was measured at baseline (n = 4956) and weeks 16, 32, and 48. Worsening renal function (WRF), defined as an increase ≥0.3 mg/dL in creatinine from baseline to week 16, was assessed via a Cox model with respect to subsequent primary events. Mean age was 69 years, 24% were female, and mean baseline eGFR was 61 mL/min/1.73 m2. During 48 weeks of treatment, the trajectories in eGFR and creatinine with vericiguat were similar to placebo (P = 0.50 and 0.18). The beneficial effects of vericiguat on the primary outcome were not influenced by baseline eGFR (interaction P = 0.48). WRF occurred in 15% of patients and was associated with worse outcomes (adjusted hazard ratio 1.28, 95% confidence interval 1.11–1.47; P < 0.001), but the beneficial effects of vericiguat on the primary outcome were similar in patients with or without WRF (interaction P = 0.76). Conclusion: Renal function trajectories were similar between vericiguat‐ and placebo‐treated patients and the beneficial effects of vericiguat on the primary outcome were consistent across the full range of eGFR and irrespective of WRF. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

29. Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial.

Author

Pieske, Burkert, Patel, Mahesh J., Westerhout, Cynthia M., Anstrom, Kevin J., Butler, Javed, Ezekowitz, Justin, Hernandez, Adrian F., Koglin, Joerg, Lam, Carolyn S.P., Ponikowski, Piotr, Roessig, Lothar, Voors, Adriaan A., O'Connor, Christopher M., Armstrong, Paul W., and VICTORIA Study Group

Subjects
HEART failure, CORONARY disease, GUANYLATE cyclase, NATRIURETIC peptides, GLOBAL studies, GLOMERULAR filtration rate
Abstract

Aim: Describe the distinguishing features of heart failure (HF) patients with reduced ejection fraction (HFrEF) in the VICTORIA (Vericiguat Global Study in Patients with Heart Failure with Reduced Ejection Fraction) trial.Methods and Results: Key background characteristics were evaluated in 5050 patients randomized in VICTORIA and categorized into three cohorts reflecting their index worsening HF event. Differences within the VICTORIA population were assessed and compared with PARADIGM-HF (Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) and COMMANDER HF (A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction, or Stroke in Participants with Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure). VICTORIA patients had increased risk of mortality and rehospitalization: New York Heart Association class (40% class III), atrial fibrillation (45%), diabetes (47%), hypertension (79%) and mean estimated glomerular filtration rate of 61.5 mL/min/1.73 m2 . Baseline standard of HF care was very good: 60% received triple therapy. Their N-terminal pro-B-type natriuretic peptide was 3377 pg/mL [interquartile range (IQR) 1992-6380]. Natriuretic peptides were 30% higher level in the 67% patients with HF hospitalization <3 months, compared to those within 3-6 months of HF hospitalization and those randomized after recent outpatient intravenous diuretic therapy. Overall the median MAGGIC (Meta-Analysis Global Group in Chronic Heart Failure) risk score in VICTORIA was 23 (IQR 18-27) as compared to the MAGGIC risk score in PARADIGM-HF of 20 (IQR 16-24).Conclusions: VICTORIA comprises a broadly generalizable high-risk population of three unique clinical strata of worsening chronic HFrEF despite very good HF therapy. VICTORIA will establish the role of vericiguat, a soluble guanylate cyclase stimulator, in HFrEF. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

30. Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations.

Author

Butler, Javed, Butler, Javed, Hamo, Carine E, Udelson, James E, O'Connor, Christopher, Sabbah, Hani N, Metra, Marco, Shah, Sanjiv J, Kitzman, Dalane W, Teerlink, John R, Bernstein, Harold S, Brooks, Gabriel, Depre, Christophe, DeSouza, Mary M, Dinh, Wilfried, Donovan, Mark, Frische-Danielson, Regina, Frost, Robert J, Garza, Dahlia, Gohring, Udo-Michael, Hellawell, Jennifer, Hsia, Judith, Ishihara, Shiro, Kay-Mugford, Patricia, Koglin, Joerg, Kozinn, Marc, Larson, Christopher J, Mayo, Martha, Gan, Li-Ming, Mugnier, Pierrre, Mushonga, Sekayi, Roessig, Lothar, Russo, Cesare, Salsali, Afshin, Satler, Carol, Shi, Victor, Ticho, Barry, van der Laan, Michael, Yancy, Clyde, Stockbridge, Norman, Gheorghiade, Mihai, Butler, Javed, Butler, Javed, Hamo, Carine E, Udelson, James E, O'Connor, Christopher, Sabbah, Hani N, Metra, Marco, Shah, Sanjiv J, Kitzman, Dalane W, Teerlink, John R, Bernstein, Harold S, Brooks, Gabriel, Depre, Christophe, DeSouza, Mary M, Dinh, Wilfried, Donovan, Mark, Frische-Danielson, Regina, Frost, Robert J, Garza, Dahlia, Gohring, Udo-Michael, Hellawell, Jennifer, Hsia, Judith, Ishihara, Shiro, Kay-Mugford, Patricia, Koglin, Joerg, Kozinn, Marc, Larson, Christopher J, Mayo, Martha, Gan, Li-Ming, Mugnier, Pierrre, Mushonga, Sekayi, Roessig, Lothar, Russo, Cesare, Salsali, Afshin, Satler, Carol, Shi, Victor, Ticho, Barry, van der Laan, Michael, Yancy, Clyde, Stockbridge, Norman, and Gheorghiade, Mihai

Abstract

The increasing burden and the continued suboptimal outcomes for patients with heart failure underlines the importance of continued research to develop novel therapeutics for this disorder. This can only be accomplished with successful translation of basic science discoveries into direct human application through effective clinical trial design and execution that results in a substantially improved clinical course and outcomes. In this respect, phase II clinical trials play a pivotal role in determining which of the multitude of potential basic science discoveries should move to the large and expansive registration trials in humans. A critical examination of the phase II trials in heart failure reveals multiple shortcomings in their concept, design, execution, and interpretation. To further a dialogue on the challenges and potential for improvement and the role of phase II trials in patients with heart failure, the Food and Drug Administration facilitated a meeting on October 17, 2016, represented by clinicians, researchers, industry members, and regulators. This document summarizes the discussion from this meeting and provides key recommendations for future directions.

Published
2017

31. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

Author

Pencina, Michael J., Green, Jennifer B., Kaufman, Keith D., Engel, Samuel S., Garg, Jyotsna, Buse, John B., Suryawanshi, Shailaja, Van De Werf, Frans, Bethel, M. Angelyn, Josse, Robert, Standl, Eberhard, Peterson, Eric D., Koglin, Joerg, Korn, Scott, Stein, Peter P., Armstrong, Paul W., Lachin, John M., McGuire, Darren K., and Holman, Rury R.

Abstract

BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. METHODS: In this randomized, double-blind study, we assigned 14,671 patients to add either sitagliptin or placebo to their existing therapy. Open-label use of antihyperglycemic therapy was encouraged as required, aimed at reaching individually appropriate glycemic targets in all patients. To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1.3 as the marginal upper boundary. The primary cardiovascular outcome was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. RESULTS: During a median follow-up of 3.0 years, there was a small difference in glycated hemoglobin levels (least-squares mean difference for sitagliptin vs. placebo, -0.29 percentage points; 95% confidence interval [CI], -0.32 to -0.27). Overall, the primary outcome occurred in 839 patients in the sitagliptin group (11.4%; 4.06 per 100 person-years) and 851 patients in the placebo group (11.6%; 4.17 per 100 person-years). Sitagliptin was noninferior to placebo for the primary composite cardiovascular outcome (hazard ratio, 0.98; 95% CI, 0.88 to 1.09; P

Published
2015
Full Text
View/download PDF

32. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document

Author

Zannad, Faiez Garcia, Angeles Alonso Anker, Stefan D. and Armstrong, Paul W. Calvo, Gonzalo Cleland, John G. F. Cohn, Jay N. Dickstein, Kenneth Domanski, Michael J. Ekman, Inger and Filippatos, Gerasimos S. Gheorghiade, Mihai Hernandez, Adrian F. Jaarsma, Tiny Koglin, Joerg Konstam, Marvin and Kupfer, Stuart Maggioni, Aldo P. Mebazaa, Alexandre Metra, Marco Nowack, Christina Pieske, Burkert Pina, Ileana L. and Pocock, Stuart J. Ponikowski, Piotr Rosano, Giuseppe and Ruilope, Luis M. Ruschitzka, Frank Severin, Thomas Solomon, Scott Stein, Kenneth Stockbridge, Norman L. Stough, Wendy Gattis Swedberg, Karl Tavazzi, Luigi Voors, Adriaan A. and Wasserman, ScottM. Woehrle, Holger Zalewski, Andrew and McMurray, John J. V.

Abstract

Endpoint selection is a critically important step in clinical trial design. It poses major challenges for investigators, regulators, and study sponsors, and it also has important clinical and practical implications for physicians and patients. Clinical outcomes of interest in heart failure trials include all-cause mortality, cause-specific mortality, relevant non-fatal morbidity (e.g. all-cause and cause-specific hospitalization), composites capturing both morbidity and mortality, safety, symptoms, functional capacity, and patient-reported outcomes. Each of these endpoints has strengths and weaknesses that create controversies regarding which is most appropriate in terms of clinical importance, sensitivity, reliability, and consistency. Not surprisingly, a lack of consensus exists within the scientific community regarding the optimal endpoint(s) for both acute and chronic heart failure trials. In an effort to address these issues, the Heart Failure Association of the European Society of Cardiology (HFA-ESC) convened a group of expert heart failure clinical investigators, biostatisticians, regulators, and pharmaceutical industry scientists (Nice, France, 1213 February 2012) to evaluate the challenges of defining heart failure endpoints in clinical trials and to develop a consensus framework. This report summarizes the groups recommendations for achieving common views on heart failure endpoints in clinical trials.

Published
2013

33. Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges

Author

Zannad, Faiez, primary, Stough, Wendy Gattis, additional, Regnault, Véronique, additional, Gheorghiade, Mihai, additional, Deliargyris, Efthymios, additional, Gibson, C. Michael, additional, Agewall, Stefan, additional, Berkowitz, Scott D., additional, Burton, Paul, additional, Calvo, Gonzalo, additional, Goldstein, Sidney, additional, Verheugt, Freek W.A., additional, Koglin, Joerg, additional, and O'Connor, Christopher M., additional

Published
2013
Full Text
View/download PDF

34. Effect of Adenosine-Regulating Agent Acadesine on Morbidity and Mortality Associated With Coronary Artery Bypass Grafting

Author

Newman, Mark F., primary, Ferguson, T. Bruce, additional, White, Jennifer A., additional, Ambrosio, Giuseppe, additional, Koglin, Joerg, additional, Nussmeier, Nancy A., additional, Pearl, Ronald G., additional, Pitt, Bertram, additional, Wechsler, Andrew S., additional, Weisel, Richard D., additional, Reece, Tammy L., additional, Lira, Armando, additional, and Harrington, Robert A., additional

Published
2013
Full Text
View/download PDF

35. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus.

Author

McGuire, Darren K., de Werf, Frans Van, Armstrong, Paul W., Standl, Eberhard, Koglin, Joerg, Green, Jennifer B., Bethel, M. Angelyn, Cornel, Jan H., Lopes, Renato D., Halvorsen, Sigrun, Ambrosio, Giuseppe, Buse, John B., Josse, Robert G., Lachin, John M., Pencina, Michael J., Garg, Jyotsna, Lokhnygina, Yuliya, Holman, Rury R., and Peterson, Eric D.

Published
2016
Full Text
View/download PDF

36. Carotid Atherosclerosis Progression in Familial Hypercholesterolemia Patients

Author

Vergeer, Menno, primary, Zhou, Rong, additional, Bots, Michiel L., additional, Duivenvoorden, Raphaël, additional, Koglin, Joerg, additional, Akdim, Fatima, additional, Mitchel, Yale B., additional, Huijgen, Roeland, additional, Sapre, Aditi, additional, de Groot, Eric, additional, Sijbrands, Eric J.G., additional, Pasternak, Richard C., additional, Gagné, Claude, additional, Marais, A. David, additional, Ballantyne, Christie M., additional, Isaacsohn, Jonathan L., additional, Stalenhoef, Anton F., additional, and Kastelein, John J.P., additional

Published
2010
Full Text
View/download PDF

38. Abstract 2223: Carotid Intima Media Thickness Progression is Modest in Statin-Treated Familial Hypercholesterolemia Patients - Results from a Patient Level Meta-Analysis of 1257 Patients

Author

Vergeer, Menno, primary, Zhou, Rong, additional, Duivenvoorden, Raphael, additional, Koglin, Joerg, additional, Mitchel, Yale B, additional, Huijgen, Roeland, additional, Sapre, Aditi, additional, Bots, Michiel L, additional, Pasternak, Richard C, additional, Gagné, Claude, additional, Marais, A D, additional, Ballantyne, Christie M, additional, Isaacsohn, Jonathan L, additional, Stalenhoef, Anton F, additional, and Kastelein, John J, additional

Published
2008
Full Text
View/download PDF

39. Abstract 2153: Taxus Atlas Long Lesion: First Report of 9-Month Clinical and Angiographic Outcomes for the TAXUS Liberté 38 mm Stent for Long Lesions

Author

Turco, Mark A, primary, Ormiston, John A, additional, Popma, Jeffrey J, additional, Weissman, Neil J, additional, Webster, Mark W, additional, Cannon, Louis A, additional, Hall, Jack J, additional, O’Shaughnessy, Charles D, additional, Mann, Tift, additional, Mandinov, Lazar, additional, Koglin, Joerg, additional, and Baim, Donald S, additional

Published
2007
Full Text
View/download PDF

41. Safety and efficacy of multiple, overlapping polymer-based paclitaxel-eluting stents

Author

Dawkins, Keith, primary, Grube, Eberhard, additional, Guagliumi, Giulio, additional, Banning, Adrian, additional, Zmudka, Krzysztof, additional, Colombo, Antonio, additional, Thuesen, Leif, additional, Hauptman, Karl, additional, Marco, Jean, additional, Wijns, William, additional, Popma, Jeffrey, additional, Weissman, Neil, additional, Koglin, Joerg, additional, and Russell, Mary, additional

Published
2007
Full Text
View/download PDF

45. Clinical Efficacy of Polymer-Based Paclitaxel-Eluting Stents in the Treatment of Complex, Long Coronary Artery Lesions From a Multicenter, Randomized Trial

Author

Dawkins, Keith D., primary, Grube, Eberhard, additional, Guagliumi, Giulio, additional, Banning, Adrian P., additional, Zmudka, Krzysztof, additional, Colombo, Antonio, additional, Thuesen, Leif, additional, Hauptman, Karl, additional, Marco, Jean, additional, Wijns, William, additional, Popma, Jeffrey J., additional, Koglin, Joerg, additional, and Russell, Mary E., additional

Published
2005
Full Text
View/download PDF

49. Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation

Author

Weissman, Neil J., primary, Koglin, Joerg, additional, Cox, David A., additional, Hermiller, James, additional, O’Shaughnessy, Charles, additional, Mann, James Tift, additional, Turco, Mark, additional, Caputo, Ronald, additional, Bergin, Patrick, additional, Greenberg, Joel, additional, Kutcher, Michael, additional, Wong, S. Chiu, additional, Strickland, Warren, additional, Mooney, Michael, additional, Russell, Mary E., additional, Ellis, Stephen G., additional, and Stone, Gregg W., additional

Published
2005
Full Text
View/download PDF

50. Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation

Author

Ellis, Stephen G., primary, Popma, Jeffrey J., additional, Lasala, John M., additional, Koglin, Joerg J., additional, Cox, David A., additional, Hermiller, James, additional, O’Shaughnessy, Charles, additional, Mann, James Tift, additional, Turco, Mark, additional, Caputo, Ronald, additional, Bergin, Patrick, additional, Greenberg, Joel, additional, and Stone, Gregg W., additional

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results